UB Paderborn / Katalog / Suche / in CDI

Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2

Journal of pharmacokinetics and pharmacodynamics, 2020-06, Vol.47 (3), p.189-198

2020

Link zum Volltext

Verfügbarkeit prüfen

Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo

Translational psychiatry, 2023-04, Vol.13 (1), p.141-141, Article 141

2023

Link zum Volltext

Verfügbarkeit prüfen

Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting

Translational psychiatry, 2023-12, Vol.13 (1), p.388-388, Article 388

2023

Link zum Volltext

Verfügbarkeit prüfen

Amyotrophic lateral sclerosis disease progression model

Amyotrophic lateral sclerosis and frontotemporal degeneration, 2014-03, Vol.15 (1-2), p.119-129

2014

Link zum Volltext

Verfügbarkeit prüfen

A convolution‐based in vitro‐in vivo correlation model for methylphenidate hydrochloride delayed‐release and extended‐release capsule

CPT: pharmacometrics and systems pharmacology, 2024-01, Vol.13 (1), p.132-142

2024

Link zum Volltext

Verfügbarkeit prüfen

Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree®): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder

Brain and behavior, 2023-04, Vol.13 (4), p.e2910-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence

Psychiatry research, 2023-09, Vol.327, p.115367-115367, Article 115367

2023

Link zum Volltext

Verfügbarkeit prüfen

First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

Clinical and translational science, 2020-01, Vol.13 (1), p.57-66

2020

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy

Journal of psychiatric research, 2008-10, Vol.42 (12), p.1000-1009

2008

Link zum Volltext

Verfügbarkeit prüfen

Use of predictive models in CNS diseases

Current opinion in pharmacology, 2014-02, Vol.14, p.23-29

Gomeni, Roberto

2014

Link zum Volltext

Verfügbarkeit prüfen

Modeling Complex Pharmacokinetics of Long‐Acting Injectable Products Using Convolution‐Based Models With Nonparametric Input Functions

Journal of clinical pharmacology, 2021-08, Vol.61 (8), p.1081-1095

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods

The AAPS journal, 2020-04, Vol.22 (3), p.67, Article 67

2020

Link zum Volltext

Verfügbarkeit prüfen

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products

Journal of pharmacokinetics and pharmacodynamics, 2023-04, Vol.50 (2), p.89-96

2023

Link zum Volltext

Verfügbarkeit prüfen

Deconvolution Analysis by Non-linear Regression Using a Convolution-Based Model: Comparison of Nonparametric and Parametric Approaches

The AAPS journal, 2019-12, Vol.22 (1), p.9-9, Article 9

2019

Link zum Volltext

Verfügbarkeit prüfen

A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials

European neuropsychopharmacology, 2013-11, Vol.23 (11), p.1570-1576

2013

Link zum Volltext

Verfügbarkeit prüfen

Model‐Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response

Clinical pharmacology and therapeutics, 2019-12, Vol.106 (6), p.1253-1260

2019

Link zum Volltext

Verfügbarkeit prüfen

EFFECT OF A SINGLE DOSE OF AMPHETAMINE EXTENDED-RELEASE TABLET ON DRIVING PERFORMANCE IN YOUNG ADULT DRIVERS WITH ADHD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A LABORATORY DRIVING ENVIRONMENT

Journal of the American Academy of Child and Adolescent Psychiatry, 2022-10, Vol.61 (10), p.S273-S274

2022

Link zum Volltext

Verfügbarkeit prüfen

Is It Time for Going Beyond the P‐Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive Disorder

Journal of clinical pharmacology, 2018-06, Vol.58 (6), p.740-749

2018

Link zum Volltext

Verfügbarkeit prüfen

Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone

Journal of clinical pharmacology, 2016-10, Vol.56 (10), p.1296-1306

2016

Link zum Volltext

Verfügbarkeit prüfen

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder

Journal of clinical psychopharmacology, 2020-07, Vol.40 (4), p.350

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating the Impact of Caffeine on the Incidence of Adverse Events During Treatment with Viloxazine Extended-Release (Qelbree®) in Adults with ADHD

CNS spectrums, 2023-04, Vol.28 (2), p.234-235

2023

Link zum Volltext

Verfügbarkeit prüfen

Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

Journal of pharmacokinetics and pharmacodynamics, 2024-08, Vol.51 (4), p.385-393

2024

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Characterization of the Smoothness of Extended-release Methylphenidate Pharmacokinetic Profiles

Innovations in clinical neuroscience, 2022-07, Vol.19 (7-9), p.32-37

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

Journal of pharmacokinetics and pharmacodynamics, 2024-08, Vol.51 (4), p.395-395

2024

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics and pharmacokinetic‐pharmacodynamic modelling of the novel H4 receptor inhibitor SENS‐111 using a modified caloric test in healthy subjects

British journal of clinical pharmacology, 2018-12, Vol.84 (12), p.2836-2848

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2

Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo

Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting

Amyotrophic lateral sclerosis disease progression model

A convolution‐based in vitro‐in vivo correlation model for methylphenidate hydrochloride delayed‐release and extended‐release capsule

Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree®): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder

A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence

First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy

Use of predictive models in CNS diseases

Modeling Complex Pharmacokinetics of Long‐Acting Injectable Products Using Convolution‐Based Models With Nonparametric Input Functions

Comparison of Alternative Population Modeling Approaches for Implementing a Level A IVIVC and for Assessing the Time-Scaling Factor Using Deconvolution and Convolution-Based Methods

Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of new LAI products

Deconvolution Analysis by Non-linear Regression Using a Convolution-Based Model: Comparison of Nonparametric and Parametric Approaches

A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials

Model‐Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response

EFFECT OF A SINGLE DOSE OF AMPHETAMINE EXTENDED-RELEASE TABLET ON DRIVING PERFORMANCE IN YOUNG ADULT DRIVERS WITH ADHD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A LABORATORY DRIVING ENVIRONMENT

Is It Time for Going Beyond the P‐Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive Disorder

Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder

Evaluating the Impact of Caffeine on the Incidence of Adverse Events During Treatment with Viloxazine Extended-Release (Qelbree®) in Adults with ADHD

Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

Quantitative Characterization of the Smoothness of Extended-release Methylphenidate Pharmacokinetic Profiles

Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

Safety, tolerability, pharmacokinetics and pharmacokinetic‐pharmacodynamic modelling of the novel H4 receptor inhibitor SENS‐111 using a modified caloric test in healthy subjects

Suchergebnisse filtern